Last updated: 23 August 2024 at 5:25pm EST

James Thrall Net Worth




The estimated Net Worth of James H Thrall is at least $3.85 million dollars as of 21 August 2024. James Thrall owns over 1,000 units of Lantheus Inc stock worth over $3,487,404 and over the last 7 years he sold LNTH stock worth over $178,250. In addition, he makes $179,993 as Independent Director at Lantheus Inc.

James Thrall LNTH stock SEC Form 4 insiders trading

James has made over 2 trades of the Lantheus Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 1,000 units of LNTH stock worth $98,520 on 21 August 2024.

The largest trade he's ever made was selling 3,500 units of Lantheus Inc stock on 6 March 2019 worth over $79,730. On average, James trades about 409 units every 181 days since 2018. As of 21 August 2024 he still owns at least 34,207 units of Lantheus Inc stock.

You can see the complete history of James Thrall stock trades at the bottom of the page.





James Thrall biography

DR. James H. Thrall serves as Independent Director of the Company. He is a Director and a member of the Nominating and Corporate Governance Committee, serving on the Board since February 2018. Dr. Thrall currently holds the Distinguished Juan M. Taveras Professorship of Radiology at Harvard Medical School, having also served as Chairman of the Department of Radiology at the Massachusetts General Hospital from 1988 until 2013. Previously, Dr. Thrall served as Chairman of Radiology at the Henry Ford Hospital between 1983 and 1988, where he also served as a Physician Trustee and held the position of Vice Chairman of the Board of Governors of the Henry Ford Medical Staff. Dr. Thrall is a member of the National Academy of Medicine and has served in leadership and board of directors positions at many U.S. and international medical and professional societies. Dr. Thrall received his M.D. from the University of Michigan in 1968 and trained in Radiology and Nuclear Medicine at the Walter Reed Army Medical Center, Washington, D.C. Dr. Thrall returned to the University of Michigan in 1975 and was promoted to Professor in 1981. Dr. Thrall was chosen as a Director because of his extensive experience in nuclear medicine and radiology, including in connection with imaging modalities and the development and use of innovative new technologies, including artificial intelligence.

What is the salary of James Thrall?

As the Independent Director of Lantheus Inc, the total compensation of James Thrall at Lantheus Inc is $179,993. There are 15 executives at Lantheus Inc getting paid more, with Mary Heino having the highest compensation of $4,320,910.



How old is James Thrall?

James Thrall is 76, he's been the Independent Director of Lantheus Inc since 2018. There are no older and 26 younger executives at Lantheus Inc.

What's James Thrall's mailing address?

James's mailing address filed with the SEC is C/O LANTHEUS HOLDINGS, INC., 201 BURLINGTON ROAD, SOUTH BUILDING, BEDFORD, MA, 01730.

Insiders trading at Lantheus Inc

Over the last 9 years, insiders at Lantheus Inc have traded over $500,725,766 worth of Lantheus Inc stock and bought 8,000 units worth $141,200 . The most active insiders traders include David F Burgstahler, Capital Partners Gp, Llc Av... et Sriram Venkataraman. On average, Lantheus Inc executives and independent directors trade stock every 11 days with the average trade being worth of $15,777,680. The most recent stock trade was executed by James H Thrall on 21 August 2024, trading 1,000 units of LNTH stock currently worth $98,520.



What does Lantheus Inc do?

lantheus holdings, inc. (nasdaq: lnth) is the parent company of lantheus medical imaging, inc. (lmi), which is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. lmi provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. lmi’s key products include the echocardiography contrast agent definity® vial for (perflutren lipid microsphere) injectable suspension; technelite® (technetium tc99m generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and xenon (xenon xe 133 gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. the company is headquartered in north billerica, massachusetts with offices in puerto rico and canada. for more information, visit www.lantheus.com.



Complete history of James Thrall stock trades at Lantheus Inc

Initié
Trans.
Transaction
Prix ​​total
James H Thrall
Vente $98,520
21 Aug 2024
James H Thrall
Vente $79,730
6 Mar 2019


Lantheus Inc executives and stock owners

Lantheus Inc executives and other stock owners filed with the SEC include: